Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. - Wikidata - wikimedia - TriplyDB

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

http://www.wikidata.org/entity/Q38883295

about

Immunotherapy for tuberculosis: future prospects Rising to the challenge: new therapies for tuberculosis Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis.Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy.The immunology of tuberculosis: from bench to bedside.Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.Advancing host-directed therapy for tuberculosis.The use of anti-tuberculosis therapy for latent TB infection Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy Tuberculosis, lung infections, interstitial lung disease, social issues and journalology in AJRCCM 2003.The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis.IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB.Zinc and infection: a review.Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors Effects of antenatal and postnatal environments on CD4 T-cell responses to Mycobacterium bovis BCG in healthy infants in the Gambia.Immunological options for the treatment of tuberculosis: evaluation of novel therapeutic approaches.Treatment of tuberculosis in children.Antigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis.Immunoregulation in TB: observations and implications Cytokine therapy of tuberculosis at the crossroads.Immunity to TB and targets for immunotherapy.Adjunct immunotherapies for tuberculosis.Immunotherapy for TB.Shortening the 'short-course' therapy- insights into host immunity may contribute to new treatment strategies for tuberculosis.Host-Directed Therapies for Tuberculosis.Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects.Immunoendocrine interactions during HIV-TB coinfection: implications for the design of new adjuvant therapies.Differences in EBA in the first two days of standard anti-tuberculosis treatment in different geographic regions.Host-Directed Therapeutic Strategies for Tuberculosis.Clinical and Immunological Effects of rhIL-2 Therapy in Eastern Chinese Patients with Multidrug-resistant Tuberculosis.New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State.TB chemotherapy: antagonism between immunity and sterilization.Immunotherapy for tuberculosis: wave of the future or tilting at windmills?

P2860

Q26741261-CA084ADA-E827-4D02-841C-FEB6214C0179 Q27011672-9B20B4DA-5321-4F89-82AA-7E91D05038A9 Q28088557-DEF1179A-7AA6-4A39-B9B9-4BCB421BCF5B Q28481571-2559A8A3-E886-4BF5-A141-76CEC47AEC39 Q33503248-64FAE75A-5BFA-43C9-A864-AEE9980AC6C6 Q33614197-17CDBCBA-611E-4062-A68E-1FD1C4CB24C3 Q33777367-32E28E5E-FA01-4922-B804-CE71C1654D0A Q33941934-5547369C-1808-40C0-85BC-C7A149B21463 Q34172161-9A90683F-F4C7-4B4A-9AEE-12CB6DF46BCA Q34466861-BA089603-3B8F-493C-80C5-026056677C16 Q35026573-CD7AE90C-8507-4D19-9199-DD6DB555304B Q35124651-B457B820-49A6-4842-A2CC-697046EA7FD2 Q35626620-D7726A7F-4D12-4B21-BDB3-8094090CF554 Q35829248-129F7F05-F2B7-4C6A-88E6-6006805DA4CA Q36142227-B8AF9CC2-58B6-46B2-8333-A7C763F464E9 Q36255320-05AA0E7E-D04A-4C0E-AC23-793DFBACC66D Q36257295-74E4245B-5555-4439-8963-224A6A51C750 Q36746866-246DCF55-23DC-41E9-8F4C-9AD0CD9A6F3A Q36839739-0DFD4901-1E85-4295-AC0D-EAB6B0DB83DA Q37340569-9F712AC7-90D5-42E7-A431-EE2E27972C9D Q37371021-C72C1FE4-0F15-46E4-8BC1-6C413ED753FA Q37742701-8C1F6A11-6CF1-493F-9EB1-C602821E63B2 Q37754962-FD1B40BC-3194-41AE-BF6E-358ECBCBE8D4 Q37984571-C5E7F38C-DDD7-4738-BE95-99D8D7BC8B8C Q37998000-D318E952-4E28-4EFE-A060-B0110E3733DC Q38025666-16628EC6-D020-4C7E-9385-B2B00A7DC089 Q38075095-AAC81DC8-45AD-4457-8BA2-DCDD21AB91A7 Q38489473-1AD92284-7B97-41A4-A844-AE26FADFBC29 Q38991212-BFAEB6D1-7ADD-42C6-8F0F-82836220D865 Q39967041-F4F85D50-47D4-4898-9774-71D55AFD95CB Q41160760-CDE3498D-32AD-465C-B392-8388B35C750C Q42580191-D238923F-183F-4C40-B957-45B1A0A5F8EC Q45006012-E96B6D0C-6A22-4B61-A5B8-49F39CD21784 Q47109821-C67E2BE3-19C0-4CD8-8AD1-B814125171D5 Q47395522-B38745FB-F3A9-48CD-9144-9B65216285A9 Q47992676-E872E58E-A253-4207-9438-903F3B2E5905 Q53924348-BEC583D1-999D-43B8-A1C8-2A6C7BE3FD4E

P2860

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

http://www.wikidata.org/entity/Q38883295

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

@en

type

label

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

@en

prefLabel

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.

@en

P1433

Q38883295-40DCF942-44B3-4892-B8A4-334B402F562E

P1476

Q38883295-A6D643B0-D052-45A5-A526-85776F2B45FA

P2093

Q38883295-16F77786-1039-404E-9D8C-FC62CC52C558

Q38883295-2CD9AC76-4B07-4038-8A75-270260917CD7

Q38883295-43D8C854-1217-4BFA-9D7C-F767C80EFDC3

Q38883295-473CE8ED-4F0A-43F2-A502-38BC5A24A983

Q38883295-6CF5F665-5044-480B-AC5D-A6CE60B0BBF1

Q38883295-7BE14B3C-DEE7-49C0-AE49-EDD8CDD53D26

Q38883295-94A3F3A8-D18E-4DC1-84FC-160B1DFD35A8

Q38883295-9DCB59D8-276F-48DB-8FC3-0E23D1971209

Q38883295-B83E1469-D5BD-475E-8B2F-FDF022AF47CF

Q38883295-FF16E71E-222E-47A2-A4D2-CDB8B132E344

P2860

Q38883295-136D5622-790B-4047-B3E9-31757C32CE83

Q38883295-138D2378-5860-4048-9B71-0DBF49379BBE

Q38883295-14E1651C-017C-4B63-B05B-3F5A453D190C

Q38883295-2CD52CDA-D7C1-48C6-B93E-A26B58EE9182

Q38883295-87AD3F96-321A-44BB-BC5F-3353D6A78295

Q38883295-908C4401-0EE2-47C0-A110-924E9E375E6B

Q38883295-AB5365C4-D1B7-4F2B-A044-0252DB790823

Q38883295-C85BE353-4DDC-4014-B8F4-4AD73674906F

Q38883295-D16D2A7B-7820-4FD9-9C57-0EA5539143FA

Q38883295-E86F7FD0-1BF9-4975-8E1D-C021CD4960F7

P304

Q38883295-D3932038-ADFB-436F-8C24-C98F8D96E37E

P31

Q38883295-BA22B4EA-E44A-4CB3-93E8-D2B87A725955

P356

Q38883295-A573C157-657F-43B3-AA80-20B84839DE67

P407

Q38883295-D4A7453A-62A6-45B4-8868-FD11ABB44CA6

P433

Q38883295-84FEC2CF-FCE1-4339-ABB3-EF7DA1D8551D

P478

Q38883295-1F2057F3-F0E4-4102-AAF1-4259BA5C648C

P50

Q38883295-94424BE3-90B5-493B-A1C6-8DE47A48781D

Q38883295-A8B8FD31-1D79-42BD-B7ED-EE5F869F8877

P577

Q38883295-26383E15-7D6A-413F-B658-96C664F42207

P5875

Q38883295-553F7705-F650-4C2D-9301-F7EADC10C8DA

P698

Q38883295-BCBF6C57-C527-4FDE-AA4B-F1F372344BDE

P921

Q38883295-28D5D345-F33F-43FB-8D15-E755E2D3A4BE

Q38883295-434E6573-4167-484D-BA4E-FAA706900A2D

P356

RCCM.200211-1359OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis

@en

P2093

Alphonse Okwera

http://www.w3.org/2001/XMLSchema#string

Christina S Hirsch

http://www.w3.org/2001/XMLSchema#string

Dana Drzayich Jankus

http://www.w3.org/2001/XMLSchema#string

Emmanuel Ssekasanvu

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Joseph G Nakibali

http://www.w3.org/2001/XMLSchema#string

Kathleen D Eisenach

http://www.w3.org/2001/XMLSchema#string

Roy D Mugerwa

http://www.w3.org/2001/XMLSchema#string

Uganda-Case Western Reserve University Research Collaboration

http://www.w3.org/2001/XMLSchema#string

W Henry Boom

http://www.w3.org/2001/XMLSchema#string

P2860

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

CD8+ T cells in tuberculosis.

The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.

Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis.

The generation of antigen-specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype. Enhancement by the cutaneous administration of interleukin 2

The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy.

Human dendritic cells presenting adenovirally expressed antigen elicit Mycobacterium tuberculosis--specific CD8+ T cells.

Guidelines for conducting tuberculin skin test surveys in high prevalence countries.

Administration of recombinant interleukin-2 reduces the local parasite load of patients with disseminated cutaneous leishmaniasis.

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

P304

185-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200211-1359OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

168

http://www.w3.org/2001/XMLSchema#string

P50

Harriet Mayanja-Kizza

P577

2003-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10797555

http://www.w3.org/2001/XMLSchema#string

P698

12702550

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde